Low Grade Serous Ovarian Carcinoma - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights:

• In 2024, the total market size of Low-Grade Serous Ovarian Cancer was ~USD 20 million in the 7MM.
• Currently, there is no standard, widely accepted screening test for ovarian cancer. This makes early detection difficult, as ovarian cancer often does not cause noticeable symptoms until it is advanced.
• Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past three decades. Although most patients respond to platinum-based treatment, the emergence of platinum resistance in recurrent ovarian cancer is inevitable during the course.
• Low responses to chemotherapy underscore the need for more effective therapies for the treatment of Low-Grade Serous Ovarian Cancer.
• Therapeutic choices varied among practitioners in recurrent settings where secondary cytoreductive surgery (CRS) was not feasible. Over a quarter opted for hormonal therapy (or change of hormones if previously on hormonal maintenance) or chemotherapy (if not previously used).
• The market of Low-Grade Serous Ovarian Cancer has seen a dynamic shift with the approvals of TAFINLAR (dabrafenib) + MEKINIST (trametinib) and AVMAPKI (avutometinib) + FAKZYNJA (defactinib) Co-pack.
• While surgery is a cornerstone of treatment, chemotherapy's efficacy is often limited, and while targeted therapies like MEK inhibitors are showing promise, they are not a cure for all. The scarce pipeline showcases the unmet need in the treatment landscape of Low-Grade Serous Ovarian Cancer and an opportunity for the industry to explore the treatment of Low-Grade Serous Ovarian Cancer.

DelveInsight's "Low-Grade Serous Ovarian Cancer (LGSOC)-Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of low-grade serous ovarian cancer, its historical and forecasted epidemiology, and the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The LGSOC market report provides current treatment practices, emerging drugs, LGSOC market share of individual therapies, and current and forecasted low-grade serous ovarian cancer market size from 2020 to 2034, segmented by seven major markets. The report also covers current low-grade serous ovarian cancer treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Low-Grade Serous Ovarian Cancer (LGSOC) Disease Understanding and Treatment Algorithm

Low-Grade Serous Ovarian Cancer (LGSOC) Overview

Ovarian cancer remains the most lethal gynecologic malignancy. Epithelial ovarian carcinoma (EOC) is the most frequent histological subtype. Based on histopathology, immunohistochemistry, and molecular analysis, EOCs are divided into five main subtypes: High-grade Serous Carcinomas (HGSOC), endometrioid carcinomas, clear-cell carcinomas, mucinous carcinomas, and Low-grade Serous Carcinomas (LGSOC). Recently, a 2-tier system in which tumors are subdivided into low-grade and high-grade has been proposed. Low-grade serous carcinomas exhibit low-grade nuclei with infrequent mitotic figures. They evolve from adenofibromas or borderline tumors, have frequent mutations of the KRAS, BRAF, or ERBB2 genes, and lack TP53 mutations. Low-grade tumors are indolent and have better outcomes than high-grade tumors.

Low-Grade Serous Ovarian Cancer (LGSOC) Diagnosis

LGSOC poses specific diagnostic challenges, often overlapping with serous borderline tumors. Pathological examination becomes pivotal, with micropapillary or cribriform features signaling potential aggressiveness and a resemblance to LGSOC behavior. Micro-invasion is present in serous borderline tumors but doesn't classify as LGSOC unless the morphology aligns with the latter. Lymph node involvement by serous borderline tumors is distinct and not considered metastatic. In the differential diagnosis, distinguishing low from high-grade serous carcinoma is crucial, as they represent distinct diseases with varying molecular profiles. Molecular profiling emerges as an opportunity for LGSOC patients, especially those with advanced-stage disease. Tumor profiling using next-generation sequencing often reveals KRAS or BRAF mutations, indicating oncogene activation, while lacking p53 loss-of-function mutations and homologous recombination deficiency. Molecular insights aid in confirming the LGSOC diagnosis, identifying treatment targets, and preventing misclassification.

Low-Grade Serous Ovarian Cancer (LGSOC) Treatment

The treatment of LGSOC primarily involves surgery, with complete cytoreduction offering the best outcomes. Fertility-sparing surgery may be considered in early-stage disease, while secondary cytoreduction is beneficial in recurrence. LGSOC is relatively chemoresistant, with platinum-based chemotherapy showing limited response; alternative cytotoxic regimens also have low efficacy and notable toxicity. Hormonal therapy, especially with aromatase inhibitors like letrozole or anastrozole, offers significant clinical benefit in both primary maintenance and recurrent settings, despite low objective response rates. Bevacizumab, an anti-angiogenic agent, has shown modest efficacy and is considered in both primary and recurrent settings. MEK inhibitors, such as trametinib, have demonstrated superior progression-free survival compared to standard therapies regardless of MAPK mutation status. CDK4/6 inhibitors (e.g., abemaciclib, ribociclib) and PI3K inhibitors (e.g., alpelisib) are emerging as promising targeted options, especially in combination with hormonal agents. Ongoing trials continue to evaluate their role, with early data supporting their efficacy and tolerability.

Low-Grade Serous Ovarian Cancer (LGSOC) Epidemiology

The LGSOC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of ovarian cancer, total incident cases of LGSOC, stage-specific cases of LGSOC, and biomarker-specific cases of LGSOC, line-wise treated cases of LGSOC in the 7MM market, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• In the 7MM, the US accounted for the highest number of incident cases of High- and low-grade serous ovarian Cancer. In the US, there were nearly 1,200 cases of LGSOC in 2024.
• Among EU4 and the UK, the UK had the highest number of cases of LGSOC, followed by Germany, whereas Spain was at the bottom of the ladder.
• MAPK cases are predominant in LGSOC in the US, in 2024 with around 630 cases.
• Data suggest that in LGSOC, the majority of cases have Stage III disease at diagnosis. About 70-80% of people are diagnosed with Stage III, and about 10% of people are diagnosed with Stage IV.

Low-grade Serous Ovarian Carcinoma (LGSOC) Drug Chapters

The drug chapter segment of the LGSOC report encloses a detailed analysis of LGSOC's marketed drugs. It also deep dives into LGSOC's pivotal clinical trial details, market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis

TAFINLAR and MEKINIST target two different kinases in the RAS/RAF/MEK/ERK pathway. The use of TAFINLAR and MEKINIST in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either drug alone.

In March 2023, the FDA approved TAFINLAR + MEKINIST for pediatric patients 1-year of age and older with LGG with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.

AVMAPKI (avutometinib) + FAKZYNJA (defactinib) Co-pack: Verastem Oncology

Avutometinib is an RAF/MEK Clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable antitumor response through maximal RAS pathway inhibition. Avutometinib blocks both RAF and MEK in a single molecule, suggesting it may help overcome resistance and ultimately block tumor growth and proliferation. By inhibiting RAF phosphorylation of MEK, avutometinib has the advantage of not inducing pMEK, and by inhibiting ERK signaling more completely, preliminary research indicates avutometinib may confer enhanced therapeutic activity. Defactinib is an oral, selective inhibitor of Focal Adhesion Kinase (FAK) and Proline-rich Tyrosine Kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases.

In May 2025, the US FDA granted accelerated approval to the combination of AVMAPKI FAKZYNJA Co-pack for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy.

Emerging Drugs

Ubamatamab (REGN4018): Regeneron Pharmaceuticals

Ubamatamab (REGN4018) is a MUC16 x cluster of differentiation 3 (MUC16xCD3) bispecific antibody that bridges MUC16 on tumor cells and CD3 on T cells to promote T cell-mediated cytotoxicity. Cemiplimab is an immune checkpoint inhibitor that targets the programmed cell death-1 (PD-1) receptor. The company is currently conducting Phase I/II trials alone or in combination with cemiplimab.

Low-grade Serous Ovarian Carcinoma (LGSOC) Drug Class Insights

Targeting the RAS/RAF/MEK/ERK pathway, also known as the MAPK pathway, has emerged as a promising therapeutic strategy in LGSOC, particularly in patients with specific genetic mutations.

Currently, two therapies dominate the LGSOC market: TAFINLAR and MEKINIST, which target different kinases within the MAPK cascade, and a novel combination therapy, AVMAPKI + FAKZYNJA, offering a differentiated mechanism of action. Avutometinib functions as a RAF/MEK clamp that forms inactive complexes with ARAF, BRAF, and CRAF, effectively suppressing MEK activation. By simultaneously inhibiting both RAF and MEK with a single molecule, avutometinib may offer more comprehensive and durable inhibition of the RAS/MAPK pathway. This dual targeting approach holds the potential to overcome resistance mechanisms and more effectively block tumor growth and proliferation in LGSOC.

Low-grade Serous Ovarian Carcinoma (LGSOC) Market Outlook

Ovarian cancer treatment typically involves a combination of surgery, chemotherapy, and targeted therapy. Surgery aims to remove cancerous tissue, while chemotherapy, administered orally or intravenously, works to shrink or destroy cancer cells. Targeted therapy blocks cancer growth and spread and is used when specific tests confirm its suitability. Currently, there are only two marketed therapies and with few emerging companies developing treatments for LGSOC. The latest approval of AVMAPKI + FAKZYNJA co-pack may create an opportunity and awareness for the researchers and companies to investigate therapies for LGSOC.

Current key players in the field include Verastem Oncology and Novartis.

• The US accounted for the largest market size of low-grade serous ovarian cancer in the 7MM, with nearly USD 15 million in 2024.
• In 2024, the UK had the largest market share among EU4 and the UK, while Spain was at the bottom of the ladder.
• The treatment for LGSOC pertains to a high-unmet need. There are only two FDA-approved treatments TAFINLAR + MEKINIST and AVMAPKI + FAKZYNJA Co-pack.

Low-grade Serous Ovarian Carcinoma (LGSOC) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to be launched in the market during the study period. The analysis covers LGSOC market uptake by drugs, patient uptake by therapies, and sales of each drug.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for ovarian cancer emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MDs, professors, and Vice Chair Department of Critical Care Medicine, and Director, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or ovarian cancer market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

DelveInsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Dana-Farber Cancer Institute, Smilow Cancer Hospital, University of Chicago etc., were contacted. Their opinion helps understand and validate ovarian cancer epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Novartis Oncology Universal Co-pay Program: Eligible patients with private insurance may pay USD 0 per month (USD 0 per month for a 30-day supply of TAFINLAR and USD 0 for a 30-day supply of MEKINIST). Co-pay of USD 0 is only for TAFINLAR and MEKINIST combination therapy. Novartis will pay the remaining co-pay, up to USD 15,000 per calendar year, per product.

Scope of the Report:

• The report covers a descriptive overview of LGSOC, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into LGSOC epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for high- and low-grade serous ovarian cancer is provided, along with the assessment of new therapies that will have an impact on the current treatment landscape.
• A detailed review of the LGSOC market, historical and forecasted, is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM high- and low-grade serous ovarian cancer market.

Low-grade Serous Ovarian Carcinoma (LGSOC) Report Insights

• Patient Population
• Therapeutic Approaches
• LGSOC Pipeline Analysis
• LGSOC Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Low-grade Serous Ovarian Carcinoma (LGSOC) Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage
• LGSOC Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Low-grade Serous Ovarian Carcinoma (LGSOC) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the LGSOC market share (%) distribution in 2020, and what will it look like in 2034?
• At what CAGR is the LGSOC market expected to grow at the 7MM level during the study period (2020-2034)?
• What are the disease risks, burdens, and unmet needs of LGSOC?
• What is the historical LGSOC patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of LGSOC?
• At what CAGR is the population expected to grow across the 7MM during the study period (2020-2034)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to LGSOC therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for LGSOC?

Reasons to buy:

• The report will help in developing business strategies by helping to understand the trends shaping and driving LGSOC.
• To understand the future market competition in the LGSOC market and an Insightful review of the SWOT analysis of high- and low-grade serous ovarian cancer.
• Organize sales and marketing efforts by identifying the best opportunities for LGSOC in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies for staying ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities in the high- and low-grade serous ovarian cancer markets.
• To understand the future market competition in the LGSOC market.